| --- | --- | |---------------------------------------|--------------------| | | | | | | | | | | | | | Oppenheimer 29 th Annual Healthcare | | | Conference | | | March 20, 2019 | | | | | | Investor materials | MED-US-DSU-1900037 | Cautionary statements 2 This presentation contains forward-looking statements, including, but not limited to, statements related to the safety, efficacy and therapeutic value of DSUVIA™ (sufentanil sublingual tablet, 30 mcg) and ZALVISO® (the sufentanil sublingual tablet system); ...